$0.43-3.2%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
The quarter ending December 31, 2013, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2013 | 3 months toDec 31, 2012 | Change |
|---|---|---|---|
| Total Revenue | $35.2M | $2.5M | +1,328.04% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Simufilam has the potential to make a meaningful difference for patients with TSC-related epilepsy. We began working toward activating clinical study sites as soon as FDA lifted the clinical hold in September. Patient screening is expected to begin by the first quarter of 2027,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
TSC-related Epilepsy Tuberous Sclerosis Complex (TSC) is a rare genetic disorder resulting from a mutation in the TSC1 or TSC2 gene. These mutations affect the mechanistic target of rapamycin (mTOR) pathway and can cause tumors to grow in multiple organs 4,5 . Epilepsy is the most common health issue affecting the TSC community, with 80% to 90% of TSC patients experiencing seizures 6 . TSC-related epilepsy affects approximately 45,000 people in the U.S. 2,4 Most patients start having seizures within their first year of life 2 . Even with multiple approved treatments, more than 60% of TSC patients remain refractory to antiepileptic therapy 7 .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Filana Therapeutics, Inc.’s Item 2.02 8-K filed November 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Filana Therapeutics, Inc. reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.